GSK licenses Noetik’s OCTO Virtual Cell Foundation Models in $50M Partnership to Advance Cancer R&D

TechBio – Linearis Portfolio Company

Jan 8th 2026

Noetik has entered into a five-year agreement with GSK, including $50M USD in upfront and licensing fees to accelerate cancer drug development in non-small cell lung and colorectal cancer research. The agreement reflects a growing shift toward licensing partnerships of AI-standalone platforms in life sciences and underscores the increasing relevance as viable business models  for BioPharma companies.

Noetik is an AI-first TechBio company focused on building generative “world models” from human tissues. Its OCTO-VC foundation models simulate tumor biology to predict patient responses and accelerate drug discovery, positioning Noetik as an innovative AI-Biotech partner. “We think that context of the data you’re using to train the models is going to be really impactful”, said Ron Alfa, co-founder and CEO of Noetik.

Press Release- BusinessWire (Jan 8th 2026) “GSK Licenses Noetik’s AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development”

Manon Boisclair MS, MBA, ICD.D

Linearis Ventures- General Partner

media@linearis.com